יחס חוב להיוון בספרים: Karyopharm Therapeutics, Inc. (KPTI)

Karyopharm Therapeutics (KPTI) automates drug synthesis using algorithms, although medicine remains central to testing. Analyzing the history of the debt-to-market cap ratio on GURU.Markets, we see that 0.00 is the current level of this metric. Karyopharm Therapeutics creates unique XPO1 inhibitors to combat myeloma, increasing its share in US clinics by expanding supportive therapy.

Karyopharm Therapeutics (KPTI) operates in the high-risk oncology biotech sector with a heavy reliance on the drug Xpovio. The calculation formula compares total liabilities to equity, quantifying the resilience of the financing structure. This ratio determines the actual debt load and the probability of default should new clinical trials fail. It is critical for investors to monitor the balance between leveraged capital and business scaling. Analyzing the percentage of debt to book capitalization allows for the timely detection of hidden financial overheating.